Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
P48059
UPID:
LIMS1_HUMAN
Alternative names:
Particularly interesting new Cys-His protein 1; Renal carcinoma antigen NY-REN-48
Alternative UPACC:
P48059; B2RAJ4; B7Z483; B7Z7R3; B7Z907; Q53TE0; Q9BS44
Background:
LIM and senescent cell antigen-like-containing domain protein 1, also known as Particularly interesting new Cys-His protein 1 and Renal carcinoma antigen NY-REN-48, plays a pivotal role in connecting beta-integrins to the actin cytoskeleton. This adapter protein facilitates the linkage of the cytoplasmic complex to cell surface receptor tyrosine kinases and growth factor receptors, crucial for cell survival, proliferation, and differentiation.
Therapeutic significance:
Understanding the role of LIM and senescent cell antigen-like-containing domain protein 1 could open doors to potential therapeutic strategies.